...
首页> 外文期刊>European journal of clinical pharmacology >Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin
【24h】

Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin

机译:雌加沙丹醛含量增加效用的比较与vonoprazan加lafutidine对胃酸抑制作用和血清胃泌素的影响

获取原文
获取原文并翻译 | 示例

摘要

Vonoprazan, a novel potassium-competitive acid blocker, elicits potent acid inhibition and hypergastrinemia at a dose of 20 mg. Its recommended maintenance dose for gastro-esophageal reflux disease is 10 mg, which is sometimes insufficient for preventing nocturnal acid breakthrough (NAB). Concomitant use of a histamine 2 receptor antagonist (H(2)RA) is effective for NAB. However, further acid inhibition by addition of H2RA has concern of hypergastrinemia again. Lafutidine (H2RA) is known to stimulate somatostatin release.
机译:vonoprazan,一种新型钾竞争性酸性阻滞剂,以20毫克的剂量引发有效的酸性抑制和高纤维肾上腺症。 其推荐的胃食管反流疾病的维持剂量为10毫克,有时不足以防止夜间酸突破(NAB)。 伴随组胺2受体拮抗剂(H(2)Ra)对Nab有效。 然而,通过添加H2RA的进一步酸性抑制再次关注高毒血症。 已知Lafutidine(H2RA)刺激生长抑素释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号